QGEN · Company research
QIAGEN N.V. (QGEN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
29records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Qiagen N.V. (QGEN) Stock Forecasts - Yahoo! Finance Canada | Qiagen N.V. (QGEN) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Qiagen N.V. (QGEN) Stock Forecasts - Yahoo Finance | Qiagen N.V. (QGEN) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| The Technical Signals Behind (QGEN) That Institutions Follow - Stock Traders Daily | The Technical Signals Behind (QGEN) That Institutions Follow Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 15, 2026 | neutral | 0 | 0.6 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight | The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight | The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| An estimated 10.7 million people developed tuberculosis in 2024. WHO warns funding cuts threaten care. - Stock Titan | An estimated 10.7 million people developed tuberculosis in 2024. WHO warns funding cuts threaten care. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest - Stocktwits | QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Qiagen (NYSE:QGEN) Stock Forecast & Analyst Predictions - Simply Wall Street | Qiagen (NYSE:QGEN) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| Qiagen (QGEN) Stock Looks Cheap Based On Future Cash Flow - Simply Wall Street | Qiagen (QGEN) Stock Looks Cheap Based On Future Cash Flow Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| BlackRock Reports Significant 11.66% Stake and 13.04% Voting Rights in Qiagen - The Globe and Mail | BlackRock Reports Significant 11.66% Stake and 13.04% Voting Rights in Qiagen The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery - Stock Titan | QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR | Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR | The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion | The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Qiagen (QGEN) Stock Surges 7.3% Amid Advanced Acquisition Talks - GuruFocus | Qiagen (QGEN) Stock Surges 7.3% Amid Advanced Acquisition Talks GuruFocus | View source ↗ | GuruFocus | Oct 2, 2026 | neutral | 0 | 0.6 |
| Qiagen (NYSE:QGEN) Shares Climb 7.7% - What's Next? - MarketBeat | Qiagen (NYSE:QGEN) Shares Climb 7.7% - What's Next? MarketBeat | View source ↗ | MarketBeat | Oct 2, 2026 | neutral | 0 | 0.6 |
| Qiagen gains on report talks with potential buyer have advanced (QGEN:NYSE) - Seeking Alpha | Qiagen gains on report talks with potential buyer have advanced (QGEN:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 2, 2026 | neutral | 0 | 0.6 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Qiagen (QGEN), What Is Behind The Fresh Attention Now? - Yahoo Finance | Qiagen (QGEN), What Is Behind The Fresh Attention Now? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51 - MarketBeat | Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51 MarketBeat | View source ↗ | MarketBeat | Sep 26, 2026 | neutral | 0 | 0.6 |
| A lab machine about the size of a sheet of printer paper processes up to eight samples per run. - Stock Titan | A lab machine about the size of a sheet of printer paper processes up to eight samples per run. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Qiagen (QGEN) Stock Faces An Execution Puzzle After Margin Rebound - Simply Wall Street | Qiagen (QGEN) Stock Faces An Execution Puzzle After Margin Rebound Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest - Yahoo Finance | QGEN Stock Clocks Biggest Single-Day Gains In Nearly Six Months – Investor Optimism Jumps On Report About Takeover Interest Yahoo Finance | View source ↗ | Yahoo Finance | Jul 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.